...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of primary care & community health. >Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Sim vast at in in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome
【24h】

Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Sim vast at in in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome

机译：瑞舒伐他汀与阿托伐他汀，普伐他汀和辛伐他汀在有或没有代谢综合征的血脂异常糖尿病患者中的成本效果，安全性和疗效比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: The aim of the current study was to determine the efficacy of the 4 most commonly prescribed statins (rosuvastatin, atorvastatin, pravastatin, and simvastatin) for managing dyslipidemia among diabetic patients with and without metabolic syndrome (MetS). Material and Methods: This was a cohort observational population-based study conducted at Hamad Medical Hospital and Primary Health Care Centre. The participants were 1542 consecutive diabetes patients who were diagnosed with dyslipidemia and were prescribed any of the indicated statins. Sociodemographic and clinical characteristics were taken from medical records, and lipid profile at baseline and 2 years after the initiation of statin therapy were retrieved from electronic medical records database (EMR-viewer). Reduction in different lipid profile after 2 years of therapy was compared among different types of statins between patients with and without MetS. Results: Out of total 1542 subjects, 562(36.4%) were diagnosed with MetS using the criteria of International Diabetes Federation. Among those with MetS, 125 were prescribed with atorvastatin, 162 pravastatin, 177 rosuvastatin, and 98 simvastatin. Among those without MetS, 365 used atorvastatin, 172 pravastatin, 345 rosuvastatin, and 98 simvastatin therapies. Among patients with MetS, rosuvastatin therapy resulted in significantly higher low-density lipoprotein cholesterol and total cholesterol reduction (23%, P = .006; and 20.3%, P = .015, respectively) as compared with other statins. Similarly, significantly higher percentage of patients receiving rosuvastatin therapy were successful in achieving the target of total cholesterol <4 mmol/L and triglycerides < 1.7 mmol/L after 2 years (38.4%, P = .012; and 67.2%, P = .010, respectively) as compared with other therapies. In contrast, among patients without MetS, rosuvastatin therapy resulted in highest percentage drop in total cholesterol (20.1%; P = .016) than other statin therapies. Conclusion: The present study confirmed that rosuvastatin therapy in commonly prescribed doses is the most effective statin for low-density lipoprotein cholesterol goal achievement and for improving the lipid profile in hypercholesterolemic diabetic patients with and without MetS.
机译：目的：本研究的目的是确定四种最常用的他汀类药物（瑞舒伐他汀，阿托伐他汀，普伐他汀和辛伐他汀）在患有和不患有代谢综合征（MetS）的糖尿病患者中治疗血脂异常的疗效。材料和方法：这是一项在哈马德医学医院和初级卫生保健中心进行的队列观察性人群研究。参与者为1542例连续的糖尿病患者，这些患者被诊断出血脂异常，并开有任何他汀类药物处方。从医疗记录中获取社会人口统计学和临床​​特征，并从电子病历数据库（EMR-viewer）中检索他汀类药物治疗开始后和基线时及开始后两年的血脂状况。比较了使用和未使用MetS的患者之间不同类型的他汀类药物治疗2年后不同脂质分布的减少情况。结果：根据国际糖尿病联合会的标准，在1542名受试者中，有562名（36.4％）被诊断出患有MetS。在那些患有MetS的患者中，有125剂处方了阿托伐他汀，162普伐他汀，177瑞舒伐他汀和98辛伐他汀。在没有MetS的患者中，有365人使用了阿托伐他汀，172种普伐他汀，345种瑞舒伐他汀和98种辛伐他汀疗法。与其他他汀类药物相比，在MetS患者中，瑞舒伐他汀疗法可显着提高低密度脂蛋白胆固醇和总胆固醇的降低（分别为23％，P = .006和20.3％，P = .015）。同样，接受瑞舒伐他汀治疗的患者在2年后成功达到总胆固醇<4 mmol / L和甘油三酯<1.7 mmol / L的目标的比例显着更高（38.4％，P = 0.012; 67.2％，P =）。与其他疗法相比）。相比之下，在没有MetS的患者中，瑞舒伐他汀治疗导致的总胆固醇下降百分比最高（20.1％; P = .016），高于其他他汀类药物治疗。结论：本研究证实，常规处方剂量的瑞舒伐他汀疗法是实现低密度脂蛋白胆固醇目标并改善高胆固醇血症糖尿病患者（不论是否患有MetS）的最有效的他汀类药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号